Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
NCT05631964Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M07D1 in gastrointestinal tumor and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limited Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
gastrointestinal tumorsolid tumor
Beyond the preview
Go deeper on NCT05631964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631964.